ProfileGDS5678 / 1451200_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 75% 74% 75% 76% 76% 75% 79% 76% 80% 74% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.780174
GSM967853U87-EV human glioblastoma xenograft - Control 24.9190774
GSM967854U87-EV human glioblastoma xenograft - Control 34.9334975
GSM967855U87-EV human glioblastoma xenograft - Control 44.9035174
GSM967856U87-EV human glioblastoma xenograft - Control 54.9468175
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9266776
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9487676
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9120975
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5297279
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0813176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6949580
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8925574
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1353576
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1114376